Literature DB >> 10822054

5'-Guanidinonaltrindole, a highly selective and potent kappa-opioid receptor antagonist.

R M Jones1, P S Portoghese.   

Abstract

5'-Guanidinonaltrindole (GNTI) possesses 5-fold greater opioid antagonist potency (K(e)=0.04 nM) and an order of magnitude greater selectivity (selectivity ratios >500) than the prototypical kappa-opioid receptor antagonist, norbinaltorphimine, in smooth muscle preparations. Binding and functional studies conducted on cloned human opioid receptors expressed in Chinese hamster ovarian (CHO) cells afforded pA(2) values that were comparable to the smooth muscle data. In view of the high selectivity and potency of GNTI, it is a potentially valuable pharmacological tool for opioid research.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10822054     DOI: 10.1016/s0014-2999(00)00208-9

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  31 in total

1.  N-Alkyl-octahydroisoquinolin-1-one-8-carboxamides: a Novel Class of Selective, Nonbasic, Nitrogen-Containing κ-Opioid Receptor Ligands.

Authors:  Kevin J Frankowski; Partha Ghosh; Vincent Setola; Thuy B Tran; Bryan L Roth; Jeffrey Aubé
Journal:  ACS Med Chem Lett       Date:  2010-08-12       Impact factor: 4.345

Review 2.  Kappa opioid antagonists: past successes and future prospects.

Authors:  Matthew D Metcalf; Andrew Coop
Journal:  AAPS J       Date:  2005-10-27       Impact factor: 4.009

3.  Micro-opioid receptor activation in the basolateral amygdala mediates the learning of increases but not decreases in the incentive value of a food reward.

Authors:  Kate M Wassum; Ingrid C Cely; Bernard W Balleine; Nigel T Maidment
Journal:  J Neurosci       Date:  2011-02-02       Impact factor: 6.167

4.  N-substituted cis-4a-(3-hydroxyphenyl)-8a-methyloctahydroisoquinolines are opioid receptor pure antagonists.

Authors:  F Ivy Carroll; Sachin Chaudhari; James B Thomas; S Wayne Mascarella; Kenneth M Gigstad; Jeffrey Deschamps; Hernán A Navarro
Journal:  J Med Chem       Date:  2005-12-29       Impact factor: 7.446

5.  The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

6.  Antagonists of the kappa-opioid receptor enhance allodynia in rats and mice after sciatic nerve ligation.

Authors:  I Obara; J Mika; M K-H Schafer; B Przewlocka
Journal:  Br J Pharmacol       Date:  2003-09-01       Impact factor: 8.739

Review 7.  Kappa-Opioid Antagonists for Psychiatric Disorders: From Bench to Clinical Trials.

Authors:  William A Carlezon; Andrew D Krystal
Journal:  Depress Anxiety       Date:  2016-10       Impact factor: 6.505

8.  Modification of the furan ring of salvinorin A: identification of a selective partial agonist at the kappa opioid receptor.

Authors:  Cécile Béguin; Katharine K Duncan; Thomas A Munro; Douglas M Ho; Wei Xu; Lee-Yuan Liu-Chen; William A Carlezon; Bruce M Cohen
Journal:  Bioorg Med Chem       Date:  2008-12-14       Impact factor: 3.641

Review 9.  Natural products as tools for neuroscience: discovery and development of novel agents to treat drug abuse.

Authors:  Thomas E Prisinzano
Journal:  J Nat Prod       Date:  2009-03-27       Impact factor: 4.050

10.  A bivalent ligand (KMN-21) antagonist for mu/kappa heterodimeric opioid receptors.

Authors:  Shijun Zhang; Ajay Yekkirala; Ye Tang; Philip S Portoghese
Journal:  Bioorg Med Chem Lett       Date:  2009-11-04       Impact factor: 2.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.